Medtide Inc. (泰德醫藥 (浙江) 股份有限公司) (Stock Code: 3880) announced that revenue for the year ended December 31, 2025 is expected to reach RMB555.00 million to RMB585.00 million, representing a year-on-year increase of 25.5% to 32.3% compared with the RMB442.20 million recorded in 2024.

The announcement further indicates that profit for 2025 is estimated to be in the range of RMB200.00 million to RMB230.00 million, marking an increase of 237.8% to 288.5% over the RMB59.20 million posted in the previous year. The adjusted net profit, a non-IFRS measure, is also forecast to be between RMB200.00 million and RMB230.00 million, up by approximately 16.3% to 33.7% compared with RMB172.00 million in 2024.

According to the announcement, the rise in revenue is attributed to the successful implementation of the “going with compound” strategy, leveraging an integrated CRDMO platform, and sustained demand from key customers. The boost in overall profit is driven by revenue growth, operational efficiencies, and fair value gains for 2025 related to financial liabilities at fair value through profit or loss. The final results for 2025 are expected to be published by the end of March 2026, subject to audit procedures.